Form 4: Processa Pharmaceuticals CEO Reports Stock Transaction
Insider Transaction (Form 4)
George K Ng, Chief Executive Officer and a Director of Processa Pharmaceuticals, Inc., reported multiple transactions in common stock on August 8, 2026.
Summary
- Option exercise/conversion: acquired 1,600 Common Stock on August 8, 2026; holds 17,092 after (Direct).
- Option exercise/conversion: disposed of 1,600 Restricted Stock on August 8, 2026; holds 19,624 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
George K Ng — Director, Officer (Chief Executive Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-08 | Option exercise/conversion | Common Stock | 1,600 | — | — | 17,092 |
| 2026-08-08 | Option exercise/conversion | Restricted Stock | 1,600 | — | — | 19,624 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-08 | Option exercise/conversion (1,600 shares) |
| 2026-08-08 | Option exercise/conversion (1,600 shares) |
Keywords
insider transaction, Form 4, PCSA, Processa Pharmaceuticals, Inc., neutral, George K Ng
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.